RAD51 in Breast Cancer: From Vulnerability to Resistance
World Journal of Oncology · 2026-08 · 17 (4) · 429-441
DOI: 10.14740/wjon2764 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift World Journal of Oncology, 2026-08. Verfasst von Rana Salman Anjum und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oral Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Homologous recombination deficiency (HRD) has transformed the therapeutic landscape of breast cancer through the clinical success of poly(ADP-ribose) polymerase (PARP) inhibitors and platinum-based chemotherapy. Central to this vulnerability is radiation sensitivity 51 (RAD51), the recombinase that executes homologous DNA repair and stabilizes stalled replication forks. In breast cancer susceptibility type 1 (BRCA1)- and breast cancer susceptibility type 2 (BRCA2)-mutant tumors, impaired RAD51 loading produces profound sensitivity to DNA-damaging agents. However, accumulating evidence indicates that restoration of RAD51 function-particularly its role in replication fork protection-is an important mechanism underlying therapeutic resistance. Beyond its canonical role in strand exchange-mediated double-strand break (DSB) repair, RAD51 orchestrates replication fork reversal, stabilization, and restart under conditions of oncogene-driven replication stress. These fork-associated functions can be mechanistically separable from classical homologous recombination and may be sufficient to confer resistance to PARP inhibitors even in tumors with persistent genomic scar signatures. Thus, breast cancer evolution under therapeutic pressure can be conceptualized as a transition from RAD51 deficiency-driven vulnerability to RAD51-dependent adaptive survival. In this review, we integrate structural, mechanistic, and translational insights into RAD51 biology and propose a dynamic framework in which replication fork protection represents a central adaptive axis in resistant breast cancer. We discuss functional biomarkers of RAD51 activity, subtype-specific dependency patterns, and emerging strategies to therapeutically target RAD51 in PARP inhibitor-refractory and replication stress-high disease. Understanding when RAD51 is deficient and when it becomes indispensable will be critical for refining precision oncology approaches in breast cancer. We argue that future precision oncology strategies must move beyond static HRD classification toward dynamic assessment of RAD51-dependent replication stress tolerance.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Oral Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.
- Department of Surgical Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.
- Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.
- Department of Surgery, University at Buffalo Jacobs School of Medicine and Biomedical Sciences the State University of New York, Buffalo, NY 14263, USA.
- Department of Breast Surgery and Oncology, Tokyo Medical University, Tokyo 160-8402, Japan.
- Department of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine, Kanagawa 236-0004, Japan.
ORCID-Profile: Rana Salman Anjum, Kazuaki Takabe
Förderung
- NCI NIH HHS
Zitieren
APA
Anjum, R. S., & Takabe, K. (2026). RAD51 in Breast Cancer: From Vulnerability to Resistance. World Journal of Oncology, 17(4), 429-441. https://doi.org/10.14740/wjon2764
Vancouver
Anjum RS, Takabe K. RAD51 in Breast Cancer: From Vulnerability to Resistance. World Journal of Oncology. 2026;17(4):429-441. doi:10.14740/wjon2764
BibTeX
@article{Anjum2026,
author = {Anjum, Rana Salman and Takabe, Kazuaki},
title = {RAD51 in Breast Cancer: From Vulnerability to Resistance},
journal = {World Journal of Oncology},
year = {2026},
volume = {17},
number = {4},
pages = {429--441},
doi = {10.14740/wjon2764}
}
EUVIMED